TrialPh 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Trial details
- Registry ID
- NCT02709512
- Phase
- Phase 2, Phase 3
PII
Polaris Group
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
6Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and CisplatinNCT02709512 | Polaris Group | Phase 2, Phase 3 | Completed | 2022-08-15Actual |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 | Polaris Group | Phase 2 | Active not recruiting | 2027-02-28Estimated |
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaNCT05317819 | Polaris Group | Phase 3 | Recruiting | 2028-09Estimated |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)NCT05712694 | Polaris Group | Phase 3 | Terminated | 2026-05-25Actual |
| Study of ADI-PEG 20 Versus Placebo in Subjects With NASHNCT05842512 | Polaris Group | Phase 2 | Recruiting | 2027-12-31Estimated |
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
Trial details
- Registry ID
- NCT04587830
- Phase
- Phase 2
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT05317819
- Phase
- Phase 3
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Trial details
- Registry ID
- NCT05712694
- Phase
- Phase 3
Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
Trial details
- Registry ID
- NCT05842512
- Phase
- Phase 2
Latest recorded trial changes
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694 · Polaris Group
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
300 participants (planned)
+ After
218 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
30 Dec 2027
+ After
25 May 2026
Recruitment status changed
− Before
Recruiting
+ After
Terminated
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
NCT05317819 · Polaris Group
Primary completion date changed
− Before
Sep 2025
+ After
Sep 2028